Richard Gaynor Net Worth

The estimated Net Worth of Richard Gaynor is at least $2.17 Million dollars as of 3 September 2024. Richard Gaynor owns over 2,500 units of Alkermes plc stock worth over $1,237,312 and over the last 6 years he sold ALKS stock worth over $134,322. In addition, he makes $797,746 as Independent Director at Alkermes plc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Richard Gaynor ALKS stock SEC Form 4 insiders trading

Richard has made over 7 trades of the Alkermes plc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 2,500 units of ALKS stock worth $48,750 on 3 September 2024.

The largest trade he's ever made was selling 65,322 units of Alkermes plc stock on 25 November 2019 worth over $85,572. On average, Richard trades about 3,813 units every 67 days since 2019. As of 3 September 2024 he still owns at least 46,568 units of Alkermes plc stock.

You can see the complete history of Richard Gaynor stock trades at the bottom of the page.

Richard Gaynor biography

Dr. Richard Gaynor, M.D. is Independent Director of the Company. Since November 2016, Dr. Gaynor has served as President of Research and Development at Neon Therapeutics, Inc. (“Neon”), a clinical stage immuno-oncology company focused on the development of neoantigen-targeted cancer therapies. Prior to joining Neon, Dr. Gaynor held roles in clinical development and medical affairs at Eli Lilly and Company (“Lilly”) from August 2002 to October 2016, including serving as Senior Vice President, Clinical Development and Medical Affairs of Lilly Oncology. During his time at Lilly, Dr. Gaynor chaired the Lilly Oncology Research and Development Committee and helped oversee various collaborations, including with General Electric, AstraZeneca, Merck and Bristol-Myers Squibb. Dr. Gaynor started his career in academia, initially serving on the faculty at UCLA School of Medicine, followed by eleven years at the University of Texas Southwestern Medical School, during which he spent time as the Chief of Hematology-Oncology and Director of the Simmons Cancer Center. Dr. Gaynor holds an M.D. from the University of Texas Southwestern Medical School and completed fellowship training in hematology-oncology at UCLA School of Medicine. Dr. Gaynor is on the editorial board of several scientific journals and has published extensively, including over 140 scientific articles. He serves on the board of directors of the Damon Runyon Cancer Research Foundation and sits on several committees for the American Association of Cancer Research and other leading cancer organizations. Dr. Gaynor is a licensed physician with board certifications in oncology and hematology.

What is the salary of Richard Gaynor?

As the Independent Director of Alkermes plc, the total compensation of Richard Gaynor at Alkermes plc is $797,746. There are 8 executives at Alkermes plc getting paid more, with Richard Pops having the highest compensation of $14,637,100.

How old is Richard Gaynor?

Richard Gaynor is 70, he's been the Independent Director of Alkermes plc since 2019. There are 3 older and 18 younger executives at Alkermes plc. The oldest executive at Alkermes plc is Dr. Floyd E. Bloom M.D., 84, who is the Founder.

What's Richard Gaynor's mailing address?

Richard's mailing address filed with the SEC is C/O ZAI LAB LIMITED, 314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE, MA, 02142.

Insiders trading at Alkermes plc

Over the last 13 years, insiders at Alkermes plc have traded over $407,046,771 worth of Alkermes plc stock and bought 86,119 units worth $2,034,840 . The most active insiders traders include Corp Plc Elan Science Three..., Richard F Pops, and James M Frates. On average, Alkermes plc executives and independent directors trade stock every 5 days with the average trade being worth of $1,083,232. The most recent stock trade was executed by David Joseph Gaffin on 3 August 2024, trading 2,014 units of ALKS stock currently worth $53,512.

What does Alkermes plc do?

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.

Complete history of Richard Gaynor stock trades at Alkermes plc, Infinity Pharmaceuticals, and Zai Lab

Alkermes plc executives and stock owners

Alkermes plc executives and other stock owners filed with the SEC include:

• Richard Pops,
  Chairman of the Board, Chief Executive Officer
• Craig Hopkinson,
  Executive Vice President, Research and Development and Chief Medical Officer
• David Gaffin,
  Senior Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
• James Frates,
  Chief Financial Officer, Senior Vice President
• Michael Landine,
  Senior Vice President - Corporate Development, Chief Risk Officer
• Richard F. Pops,
  Chairman & CEO
• Dr. Craig C. Hopkinson,
  Exec. VP of R&D and Chief Medical Officer
• David Joseph Gaffin,
  Sr. VP, Chief Legal Officer, Chief Compliance Officer & Sec.
• Frank Wilson,
  Independent Director
• Richard Gaynor,
  Independent Director
• Michael J. Landine,
  Sr. VP of Corp. Devel. & Chief Risk Officer
• Paul Mitchell,
  Independent Director
• Robert Breyer,
  Independent Director
• David Anstice,
  Lead Independent Director
• Nancy Snyderman,
  Independent Director
• Wendy Dixon,
  Independent Director
• Nancy Wysenski,
  Independent Director
• Shane Cooke,
  Director
• Iain Brown,
  Senior Vice President - Finance, Chief Accounting Officer
• Peter Norman,
  Sr. VP of Policy & Gov. Relations
• Iain Michael Brown,
  Sr. VP & CFO
• Dr. Floyd E. Bloom M.D.,
  Founder
• Stephen Schiavo,
  Sr. VP of HR
• Eva Stroynowski,
  VP of Product & R&D Communications, Public Affairs
• Sandra Coombs,
  Co-Head of Investor Relations
• Blair C. Jackson,
  Exec. VP & COO
• Dr. Floyd E. Bloom,
  Founder
• Floyd E Bloom,
  Director
• Elliot Ehrich,
  SVP, R&D & CMO, Alkermes, Inc.
• Mark Stejbach,
  Chief Commercial Officer
• James A. Jr. Robinson,
  President & COO,Alkermes, Inc.
• Nancy Lurker,
  Director
• Rebecca Peterson,
  SVP, Corporate Communications
• Geraldine Henwood,
  Director
• Kathryn L Biberstein,
  SVP, GC, Secretary, Alks, Inc.
• Gordon G Pugh,
  SVP, COO & CRO, Alkermes, Inc.
• James L Botkin,
  SVP, Alkermes Gainesville LLC
• Mark B Skaletsky,
  Director
• Corp Plc Elan Science Three...,
  
• Christian Todd Nichols,
  SVP, Chief Commercial Officer
• Brian P Mckeon,
  Director
• David Angelo Jr. Daglio,
  Director
• Blair Curtis Jackson,
  EVP, Chief Operating Officer
• Emily Peterson Alva,
  Director
• Cato T Laurencin,
  Director
• Christopher I Wright,
  Director
• Samuel Joseph Parisi,
  VP, Finance (Interim PAO)